Spotlight-listed Cereno Scientific recently released its third quarter report. During the period, the company reached several milestones, the most significant being when FDA accepted Cereno’s IND application for the phase II trial with drug candidate CS1. CEO Sten R Sörensen elaborated in BioStock’s studio interview.
Watch the full interview with Cereno Scientific’s CEO Sten R Sörensen below. The interview is in Swedish.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.